Cargando…

盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察

BACKGROUND AND OBJECTIVE: Icotinib is the first self-developed small molecular drug in China for targeted therapy of lung cancer. Compared to the other two commercially available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, icotinib is similar to them...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015183/
https://www.ncbi.nlm.nih.gov/pubmed/26706949
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.12.04
_version_ 1783334353737089024
collection PubMed
description BACKGROUND AND OBJECTIVE: Icotinib is the first self-developed small molecular drug in China for targeted therapy of lung cancer. Compared to the other two commercially available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, icotinib is similar to them in chemical structure, mechanism of activity and therapeutic effects. To explore the efficacy and side effects of icotinib hydrochloride in the treatment of the advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation and wild-type. METHODS: Patients with advanced NSCLC who were treated with icotinib hydrochloride in Beijing Chest Hospital were retrospective analyzed from March 2009 to December 2014. RESULTS: The clinical data of 124 patients (99 with EGFR mutation and 25 with wild type) with advanced NSCLC were enrolled in this study. The patients' overall objective response rate (ORR) was 51.6 % and the disease control rate (DCR) was 79.8%; The patients with EGFR mutation, ORR was 63.6%, DCR was 93.9%. The ORR was 4.0% and the DCR was 24.0% in the wild-type patients. Median progression-free survival (PFS) with icotinib treatment in EGFR mutation patients was 10.5 months and 1.0 month in wild-type patients. The major adverse events were mild skin rash (30.6%) and diarrhea (16.1%). CONCLUSION: Monotherapy with icotinib hydrochloride is effective and tolerable for the advanced NSCLC EGFR mutation patients.
format Online
Article
Text
id pubmed-6015183
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60151832018-07-06 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Icotinib is the first self-developed small molecular drug in China for targeted therapy of lung cancer. Compared to the other two commercially available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, icotinib is similar to them in chemical structure, mechanism of activity and therapeutic effects. To explore the efficacy and side effects of icotinib hydrochloride in the treatment of the advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation and wild-type. METHODS: Patients with advanced NSCLC who were treated with icotinib hydrochloride in Beijing Chest Hospital were retrospective analyzed from March 2009 to December 2014. RESULTS: The clinical data of 124 patients (99 with EGFR mutation and 25 with wild type) with advanced NSCLC were enrolled in this study. The patients' overall objective response rate (ORR) was 51.6 % and the disease control rate (DCR) was 79.8%; The patients with EGFR mutation, ORR was 63.6%, DCR was 93.9%. The ORR was 4.0% and the DCR was 24.0% in the wild-type patients. Median progression-free survival (PFS) with icotinib treatment in EGFR mutation patients was 10.5 months and 1.0 month in wild-type patients. The major adverse events were mild skin rash (30.6%) and diarrhea (16.1%). CONCLUSION: Monotherapy with icotinib hydrochloride is effective and tolerable for the advanced NSCLC EGFR mutation patients. 中国肺癌杂志编辑部 2015-12-20 /pmc/articles/PMC6015183/ /pubmed/26706949 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.12.04 Text en 版权所有©《中国肺癌杂志》编辑部2015 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察
title 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察
title_full 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察
title_fullStr 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察
title_full_unstemmed 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察
title_short 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察
title_sort 盐酸埃克替尼治疗egfr突变状态明确的晚期非小细胞肺癌的临床观察
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015183/
https://www.ncbi.nlm.nih.gov/pubmed/26706949
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.12.04
work_keys_str_mv AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá
AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá
AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá
AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá
AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá
AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá
AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá
AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá
AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá
AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá
AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá